香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 本公告僅作參考用途，並不構成收購、購買或認購本公司任何證券之邀請或要約。 Jinhai Medical Technology Limited 1 對本公司股權架構的影響 下文分別列出本公司(i)緊接完成前；及(ii)緊隨完成後之股權架構： | | 緊接完成前 | | 緊隨完成後 | | | --- | --- | --- | --- | --- | | | 股份數目 | 概約百分比 | 股份數目 | 概約百分比 | | 寶來國際有限公司 | | | | | | （附註1） | 2,530,000,000 | 48.94 | 2,530,000,000 | 47.82 | | 認購人A | – | – | 40,000,000 | 0.76 | | 認購人B | – | – | 40,000,000 | 0.76 | | 認購人C | – | – | 40,000,000 | 0.76 | | 其他公眾股 ...

Key Points - As of August 15, a total of 133 stocks reached their 52-week highs, with notable performers including 瑞港建设 (RuiGang Construction) at 94.74%, 力劲科技 (LiJing Technology) at 60.74%, and 派格生物医药－Ｂ (PAG Biopharma-B) at 39.18% [1] - The highest closing prices were recorded for 瑞港建设 at 0.260, 力劲科技 at 6.790, and 派格生物医药－Ｂ at 32.000 [1] - Other significant stocks that reached new highs include FIT HON TENG at 5.970 (26.04%), 远大中国 at 0.153 (25.81%), and 百心安－Ｂ at 6.060 (25.60%) [1] - The report also highlights stocks that reached their 52-week lows, with 今海医疗科技 (JinHai Medical Technology) dropping to 0.890 (-49.45%) and 恒泰裕集团 (HengTai Yu Group) at 0.014 (-12.50%) [4] - The overall market trend indicates a mix of strong performers and struggling stocks, reflecting varying investor sentiments across different sectors [1][4]

公告称，集团拟将认购事项所得款项用于为潜在并购医疗保健相关项目及╱或公司及投资医疗保健相关 产业提供资金；研发开支；及一般营运资金。 本文源自智通财经网 智通财经获悉，今海医疗科技(02225)盘中跌超36%，早盘一度跌超65%。截至发稿，跌36.11%，报1.15 港元，成交额1.61亿港元。 消息面上，今海医疗科技近期发布公告，公司(作为发行人)就认购事项与三名认购人订立三份认购协 议，以认购价每股股份1.35港元认购合共1.2亿股认购股份。各认购人为独立私人投资者。认购价为每股 股份1.35港元，较于认购协议日期联交所所报收市价每股股份1.64港元折让约17.68%；认购事项所得款 项净额(经扣除认购事项所有适用成本及开支)将约为1.6亿港元，而净发行价约为每股认购股份1.34港 元。 ...

消息面上，今海医疗科技近期发布公告，公司(作为发行人)就认购事项与三名认购人订立三份认购协 议，以认购价每股股份1.35港元认购合共1.2亿股认购股份。各认购人为独立私人投资者。认购价为每股 股份1.35港元，较于认购协议日期联交所所报收市价每股股份1.64港元折让约17.68%；认购事项所得款 项净额(经扣除认购事项所有适用成本及开支)将约为1.6亿港元，而净发行价约为每股认购股份1.34港 元。 公告称，集团拟将认购事项所得款项用于为潜在并购医疗保健相关项目及╱或公司及投资医疗保健相关 产业提供资金；研发开支；及一般营运资金。 今海医疗科技(02225)盘中跌超36%，早盘一度跌超65%。截至发稿，跌36.11%，报1.15港元，成交额 1.61亿港元。 ...

Core Viewpoint - Jin Hai Medical Technology (02225) experienced a significant decline in stock price, dropping over 36% during trading, with an intraday drop exceeding 65% [1] Group 1: Stock Performance - As of the report, the stock price of Jin Hai Medical Technology was down 36.11%, trading at 1.15 HKD, with a trading volume of 161 million HKD [1] - The company announced a subscription agreement with three independent private investors to issue a total of 120 million shares at a subscription price of 1.35 HKD per share [1] Group 2: Subscription Details - The subscription price of 1.35 HKD represents a discount of approximately 17.68% compared to the closing price of 1.64 HKD on the date of the subscription agreement [1] - The net proceeds from the subscription, after deducting all applicable costs and expenses, are expected to be around 160 million HKD, with a net issuance price of approximately 1.34 HKD per share [1] Group 3: Use of Proceeds - The company plans to use the proceeds from the subscription for potential acquisitions in the healthcare sector, funding for healthcare-related projects, research and development expenses, and general working capital [1]

Group 1 - The core business of the company is as a service provider, primarily offering labor dispatch and supporting services to construction contractors in Singapore, along with dormitory services, IT services, and construction support services [2] - The company aims to leverage the advantages of both Hong Kong and Singapore to actively expand its existing business, enter new industries, and seek investment cooperation opportunities to enhance long-term returns for shareholders and improve business prospects [2] Group 2 - As of August 14, the company's stock price increased by 20.0% to HKD 1.8 per share, with a trading volume of 22.13 million shares and a turnover of HKD 33.81 million, showing a volatility of 25.33% [1] - Financial data indicates that for the year ending December 31, 2024, the company achieved total revenue of HKD 267 million, a year-on-year increase of 10.07%, while the net profit attributable to shareholders was a loss of HKD 95.6 million, a decrease of 471.95% [1] - The company's gross profit margin stands at 22.84%, and its debt-to-asset ratio is 44.32% [1] - Currently, there are no institutional investment ratings for the company's stock [1] - The company's price-to-earnings ratio is -75.12, ranking 57th in the industry, while the average price-to-earnings ratio for the support services industry is 5.63 [1]

公司名稱: 今海醫療科技股份有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02225 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 8,000,000,000 | HKD | | 0.0025 | HKD | | 20,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 8,000,000,000 | HKD | | 0.0025 | HKD | | 20,000,000 | 本月底法定/註冊股本總額： HKD 20,000,000 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31 ...

Company Overview - Jinhai Medical Technology Co., Ltd. (stock code: 02225.HK) operates primarily in the service provider sector, offering labor dispatch and supporting services to construction contractors in Singapore, along with dormitory, IT, and construction support services [2] - The company aims to leverage its advantages in Hong Kong and Singapore to expand its existing business, enter new industries, and seek investment cooperation opportunities to enhance long-term returns for shareholders [2] Financial Performance - As of December 31, 2024, Jinhai Medical reported total revenue of 267 million yuan, representing a year-on-year growth of 10.07% [1] - The company recorded a net profit attributable to shareholders of -95.599 million yuan, a significant decrease of 471.95% compared to the previous year [1] - The gross profit margin stood at 22.84%, while the debt-to-asset ratio was 44.32% [1] Market Performance - On July 17, the Hang Seng Index closed down 0.08% at 24,498.95 points, while Jinhai Medical's stock price increased by 11.52% to 1.84 HKD per share, with a trading volume of 4.035 million shares and a turnover of 7.2649 million HKD [1] - Over the past month, Jinhai Medical's stock has seen a cumulative increase of 20.44%, but it has declined by 13.16% year-to-date, underperforming the Hang Seng Index by 22.22% [1] Valuation Metrics - Currently, there are no institutional investment ratings for Jinhai Medical [2] - The average price-to-earnings (P/E) ratio for the support services industry (TTM) is 3.73, with a median of 3.77 [2] - Jinhai Medical's P/E ratio is -82.63, ranking 57th in the industry, compared to other companies in the Chinese education sector with P/E ratios ranging from 1.47 to 2.8 [2] Corporate Actions - On July 13, 2025, the company plans to issue 120 million new shares, representing 2.27% of the enlarged share capital, at a subscription price of 1.35 HKD per share, which is a 17.68% discount to the previous closing price [3]

Market Performance - Today, Hong Kong stocks showed significant movements with various companies experiencing notable gains, including Now Medical Technology (02225) which rose over 5% after a partnership with David Medical to develop "Minimally Invasive 5.0" technology [1] - Semiconductor stocks also saw an uptick, with Huahong Semiconductor (01347) increasing by 4.12%, and SMIC (01347) rising by 3.11% [1][2] - Hong Kong Travel (00308) surged over 14%, doubling its stock price in less than a month, driven by speculation in the tourism industry [1] - Meituan-W (03690) rose over 3% as it led an investment in Star Sea Map, furthering its focus on embodied intelligence [1] - The insurance sector saw broad gains, with China Pacific Insurance (02601) up 4.88% and China Life Insurance (02318) increasing by 3.19% [1] Company-Specific Developments - Alibaba-W (09988) increased over 3%, although its investment in instant retail and delivery services may impact profitability, according to HSBC [2] - Qian Shi International (00381) skyrocketed by over 55% due to a proposed digital economy collaboration involving a stablecoin mechanism [2] - Stablecoin-related stocks rose, with Guotai Junan International (01788) up 9.13% and China Everbright Holdings (00165) increasing by 4.83% [2] - Yadi Holdings (01585) gained over 4% following the announcement of a new electric vehicle replacement program [3] - WuXi AppTec (02359) opened nearly 5% higher after announcing expected revenue exceeding 20 billion yuan and a projected doubling of net profit [3] Industry Trends - The electric vehicle sector is expected to see growth due to a new replacement program, which could accelerate industry expansion [3] - The rare earth sector is also experiencing upward momentum, with Jinli Permanent Magnet (06680) rising over 5% after major players announced price increases [3] - The biotechnology sector is witnessing positive developments, with Xiansheng Pharmaceutical (02096) gaining over 3% after a collaboration with Conade Biopharmaceuticals [2][3]

[Supplementary Announcement Overview](index=1&type=section&id=Supplementary%20Announcement%20Overview) This announcement provides supplementary information to the company's 2024 annual report, focusing on risk management remedies and share option scheme updates [Purpose and Background of the Announcement](index=1&type=section&id=Purpose%20and%20Background) This announcement supplements the company's 2024 annual report, detailing risk management remedies and share option scheme updates - This document is a supplementary announcement by Jinhai Medical Technology Co., Ltd. (Stock Code: 2225) regarding its 2024 annual report[2](index=2&type=chunk) - The announcement aims to provide supplementary information beyond the annual report, covering risk management, internal control, and the share option scheme[3](index=3&type=chunk)[4](index=4&type=chunk) [Risk Management and Internal Control Enhancement Measures](index=1&type=section&id=Risk%20Management%20and%20Internal%20Control%20Enhancement) The board has implemented various remedial measures to strengthen risk management and internal controls, ensuring compliance with listing rules [Details of Remedial Measures](index=1&type=section&id=Remedial%20Measures) The Board implemented risk management and internal control remedies to prevent future non-compliance and ensure adherence to Listing Rules Chapter 14 - The Board confirms its responsibility to maintain sound and effective risk management and internal control systems, having acted on identified deficiencies[4](index=4&type=chunk) - The company has implemented several remedial measures to ensure future compliance with Listing Rules Chapter 14, including strengthening internal control policies for notifiable transactions, providing internal training on Listing Rules for directors and management, hiring qualified staff to oversee future transactions and size test calculations, and seeking external professional advice for all proposed transactions[7](index=7&type=chunk)[5](index=5&type=chunk) [Share Option Scheme Update](index=2&type=section&id=Share%20Option%20Scheme%20Update) This section provides an update on the share option scheme, specifically detailing the number of options available for grant [Number of Share Options Available for Grant](index=2&type=section&id=Number%20of%20Share%20Options%20Available%20for%20Grant) The announcement details the number of share options available for grant under the scheme mandate and service provider sub-limits for fiscal year 2024, showing zero options at year-end Share Options Available for Grant | Category | January 1, 2024 | December 31, 2024 | | :--- | :--- | :--- | | Scheme Mandate Limit | 517,000,000 | 0 | | Service Provider Sub-limit | 51,700,000 | 0 | *Note: Numbers have been adjusted with reference to the share split effective December 10, 2024* [Other Information](index=3&type=section&id=Other%20Information) This section confirms the consistency of the annual report's other contents and lists the current composition of the Board of Directors [Concluding Remarks and Board Composition](index=3&type=section&id=Concluding%20Remarks%20and%20Board%20Composition) The announcement confirms the annual report's other contents remain unchanged, except for supplementary details, and lists the Board's composition as of the announcement date - All other information within the annual report remains unchanged, except for the supplementary details disclosed in this announcement[8](index=8&type=chunk) - As of the announcement date, the Board of Directors comprises eight members: three executive directors, two non-executive directors, and three independent non-executive directors[9](index=9&type=chunk)